Roberto Mina, MD, discussed the significance of the early outcomes that were reported from the MajesTEC-9 trial in patients with relapsed/refractory multiple myeloma.
Roberto Mina, MD
Advertisement
Roberto Mina is an associate professor at Winship Cancer Institute of Emory University and former assistant professor at University of Turin in Italy.
Articles by Roberto Mina, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
New OrigAMI-1 Data Signal Shift Beyond First-Gen EGFR Inhibitors in Metastatic CRC
2
The Targeted Pulse: Lung Cancer Advancements and FDA Decisions
3
Breakthroughs in Oncology: Validating Real Gains in Cancer Survival
4
EMA Validates T-DXd for First-Line HER2+ Metastatic Breast Cancer
5